Small molecule · Inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) (CBLB) · developed by Nurix Therapeutics
NX-1607 is an orally bioavailable small-molecule inhibitor of CBL-B, an E3 ubiquitin ligase that negatively regulates immune activation in leukocytes including T cells and NK cells. By inhibiting CBL-B, it is intended to promote NK cell and activated CD8+ T-cell infiltration of the tumor microenvironment. It is being studied in multiple solid tumors and lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05107674 | Phase 1 | Ovarian Cancer, Epithelial | Recruiting | NRIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Gastric CancerGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMalignant Pleural Mesothelioma (MPM)Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic or Unresectable MelanomaMetastatic Urothelial CarcinomaMicrosatellite Stable Colorectal CarcinomaNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer, EpithelialRichter TransformationTriple Negative Breast Cancer (TNBC)
See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRIX catalysts and pipeline →